CoVac-1, a COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies, including those with lymphoma and leukemia, according to study results presented during American Association for Cancer Research Annual Meeting.
“CoVac-1-induced T cell responses were documented in all but one of these highly immunocompromised patients,” Juliane Walz, MD, professor of peptide-based immunotherapy at University Hospital Tübingen in Germany, and Claudia Tandler, MSc, graduate student in the department of peptide-based immunotherapy at University of Tübingen, told